The Efficacy of Immunomodulators in the Prevention and Suppression of Anti-drug Antibodies to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Overview

Journal Ann Gastroenterol

Specialty Gastroenterology

Date 2022 Jan 6

PMID 34987282

Citations 7

Authors

Fotios S Fousekis

Konstantinos Papamichael

Georgios Kourtis

Eleni N Albani

Afroditi Orfanidou

Maria Saridi

Konstantinos H Katsanos

Dimitrios K Christodoulou

Affiliations

Soon will be listed here.

Abstract

The development of biological agents against tumor necrosis factor (TNF) has revolutionized the management of inflammatory bowel disease (IBD), frequently achieving induction and maintenance of remission in both ulcerative colitis and Crohn's disease. However, a loss of response due to the development of anti-drug antibodies (ADA) is seen annually in approximately 20% of IBD patients receiving anti-TNF therapy. Current evidence suggests that the use of immunomodulators (IMM), such as thiopurines (azathioprine and 6-mercaptopurine) or methotrexate, may prevent or suppress ADA formation. In this article, we present a comprehensive review of the available literature regarding the efficacy of IMM in the prevention and suppression of ADA development to anti-TNF therapy in patients with IBD.

Citing Articles

Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease-Reports from a Romanian Center.

Matran R, Diaconu A, Iordache A, Dijmarescu I, Coroleuca A, Pacurar D Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861147 PMC: 11768541. DOI: 10.3390/ph18010084.

Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.

Manzano G, Eaton J, Levy M, Abbatemarco J, Aksamit A, Anand P Neurol Clin Pract. 2025; 15(2):e200429.

PMID: 39830676 PMC: 11737638. DOI: 10.1212/CPJ.0000000000200429.

Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China.

Jin X, Sun K, Wang L, Shen H, Ma D, Shen T Therap Adv Gastroenterol. 2025; 18:17562848241307598.

PMID: 39758966 PMC: 11696958. DOI: 10.1177/17562848241307598.

Infliximab trough levels among patients with inflammatory bowel disease in correlation with infliximab treatment escalation: a cross-sectional study from a Greek tertiary center.

Orfanidou A, Katsanos K, Voulgaris T, Kofinas A, Christodoulou M, Konstandi M Ann Gastroenterol. 2024; 37(6):674-681.

PMID: 39568710 PMC: 11574158. DOI: 10.20524/aog.2024.0926.

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.

Nielsen O, Hammerhoj A, Ainsworth M, Gubatan J, DHaens G Drugs. 2024; 85(1):67-85.

PMID: 39532820 DOI: 10.1007/s40265-024-02115-3.

References

Fiorino G, Ruiz-Arguello M, Maguregui A, Nagore D, Correale C, Radice S . Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(3):601-606. DOI: 10.1093/ibd/izx086. View

Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S . Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014; 12(9):1474-81.e2. DOI: 10.1016/j.cgh.2014.01.033. View

Osterman M, Sandborn W, Colombel J, Robinson A, Lau W, Huang B . Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2013; 146(4):941-9. DOI: 10.1053/j.gastro.2013.12.025. View

Feagan B, McDonald J, Panaccione R, Enns R, Bernstein C, Ponich T . Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2013; 146(3):681-688.e1. DOI: 10.1053/j.gastro.2013.11.024. View

Ong D, Kamm M, Hartono J, Lust M . Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013; 28(10):1595-9. DOI: 10.1111/jgh.12263. View

Goncalves J, Myung G, Park M, Jeong D, Ghil J . SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therap Adv Gastroenterol. 2019; 12:1756284819891081. PMC: 6893927. DOI: 10.1177/1756284819891081. View

Lowenberg M . Is there a beneficial effect of adding azathioprine to adalimumab in Crohn's disease patients?. Ann Transl Med. 2018; 6(13):278. PMC: 6064807. DOI: 10.21037/atm.2018.06.36. View

Ben-Horin S, Ungar B, Roblin X . Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Aliment Pharmacol Ther. 2017; 45(5):760-762. DOI: 10.1111/apt.13932. View

Holmstrom R, Mogensen D, Brynskov J, Ainsworth M, Nersting J, Schmiegelow K . Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018; 63(6):1583-1591. DOI: 10.1007/s10620-018-5020-9. View

10.

Jorgensen K, Goll G, Sexton J, Bolstad N, Olsen I, Asak O . Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials. BioDrugs. 2020; 34(5):681-694. PMC: 7519917. DOI: 10.1007/s40259-020-00438-7. View

11.

Papamichael K, Vajravelu R, Osterman M, Cheifetz A . Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018; 63(3):761-767. PMC: 5823777. DOI: 10.1007/s10620-018-4917-7. View

12.

Fine S, Papamichael K, Cheifetz A . Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2020; 15(12):656-665. PMC: 6935028. View

13.

Macaluso F, Cummings J, Atreya R, Choi J, Orlando A . A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. Expert Opin Biol Ther. 2021; 22(2):203-223. DOI: 10.1080/14712598.2021.1958778. View

14.

Bar-Yoseph H, Waterman M, Almog R, Billiet T, Vermeire S, Ungar B . Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines. Clin Gastroenterol Hepatol. 2016; 15(1):69-75. DOI: 10.1016/j.cgh.2016.06.028. View

15.

Adedokun O, Xu Z, Liao S, Strauss R, Reinisch W, Feagan B . Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther. 2020; 42(1):157-174.e4. DOI: 10.1016/j.clinthera.2019.11.010. View

16.

Papamichael K, Chachu K, Vajravelu R, Vaughn B, Ni J, Osterman M . Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 2017; 15(10):1580-1588.e3. PMC: 5605429. DOI: 10.1016/j.cgh.2017.03.031. View

17.

DHaens G, van Deventer S . 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021; 70(7):1396-1405. DOI: 10.1136/gutjnl-2019-320022. View

18.

Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber S . Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021; 6(10):816-825. DOI: 10.1016/S2468-1253(21)00252-1. View

19.

Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B . Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2015; 65(7):1132-8. DOI: 10.1136/gutjnl-2015-309290. View

20.

Chaparro M, Gisbert J . Maintenance therapy options for ulcerative colitis. Expert Opin Pharmacother. 2016; 17(10):1339-49. DOI: 10.1080/14656566.2016.1187132. View